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ABSTRACT
Adoptive therapy with engineered T cells shows promising results in treating patients with malignant
disease, but is challenged by incomplete responses and tumor recurrences. Here, we aimed to direct the
tumor microenvironment in favor of a successful immune response by local secretion of interleukin (IL-) 12
and IL-18 by sadministered T cells. To this end, we engineered T cells with a melanoma-speciﬁc T cell
receptor (TCR) and murine IL-12 and/or IL-18 under the control of a nuclear-factor of activated T-cell
(NFAT)-sensitive promoter. These T cells produced IL-12 or IL-18, and consequently enhanced levels of
IFNg , following exposure to antigen-positive but not negative tumor cells. Adoptive transfer of T cells with
a TCR and inducible (i)IL-12 to melanoma-bearing mice resulted in severe, edema-like toxicity that was
accompanied by enhanced levels of IFNg and TNFa in blood, and reduced numbers of peripheral TCR
transgene-positive T cells. In contrast, transfer of T cells expressing a TCR and iIL-18 was without side
effects, enhanced the presence of therapeutic CD8C T cells within tumors, reduced tumor burden and
prolonged survival. Notably, treatment with TCRCiIL-12 but not iIL-18 T cells resulted in enhanced intra-
tumoral accumulation of macrophages, which was accompanied by a decreased frequency of therapeutic
T cells, in particular of the CD8 subset. In addition, when administered to mice, iIL-18 but not iIL-12
demonstrated a favorable proﬁle of T cell co-stimulatory and inhibitory receptors. In conclusion, we
observed that treatment with T cells engineered with a TCR and iIL18 T cells is safe and able to skew the
tumor microenvironment in favor of an improved anti-tumor T cell response.
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Introduction
Up to now, dozens of clinical trials have demonstrated the
effectiveness of adoptive therapy with T cells that are gene-
engineered with T cell receptors (TCRs) or chimeric antigen
receptors (CARs). Therapeutic successes are most prominent
for the treatment of hematological malignancies,1-6 whereas in
the majority of patients with solid tumors, initial regressions
are challenged by rapid tumor recurrences.
Patient responsiveness to immune therapies appears to be
related to numbers and location of tumor inﬁltrating lympho-
cytes (TILs).7,8 Tumors that have low or negligible numbers of
TILs may demonstrate intrinsic changes that result in limited T
cell inﬁltration, movement and activation, and as such pose
barriers to T cell treatments when compared to tumors with
high numbers of TILs.9,10 In fact, predictive value towards
response to clinical T cell therapies has recently been attributed
to determinants of immunogenicity, such as extent of antigen
presentation, composition of immune inﬁltrates, and presence
of inhibitors of T cell activity.11 Expectedly, intervention with
such determinants has the ability to enhance the sensitivity of
tumors for T cell treatment.12
Here, we investigated to what extent local depositions of IL-
12 and IL-18 in the tumor tissue would enhance the efﬁcacy of
adoptive T cell therapy. IL-12 is a heterodimer that consists of
the subunits p35 and p40 and, although primarily produced by
antigen-presenting cells, it is also a product of T cells.13,14 Initial
studies showed IL-12’s ability to enhance the cytolytic activity
of T cells,15 aid in the recruitment of macrophages,16 and
induce a TNFa-mediated shift towards M1-type macro-
phages.17,18 IL-18 is a pro-inﬂammatory IL-1-like cytokine that
is primarily produced by macrophages and is able to drive T
and NK cell maturation (reviewed in19). Both cytokines enable
an immunological shift towards Th1-type T cell responses.
Notably, IL-12 increases the proportion of T cells expressing
the IL-18 receptor 1 subunit (IL-18R1), resulting in further
enhancement of IFNg production by IL-12 plus IL-18-stimu-
lated T cells.20,21 Despite IL-12’s beneﬁcial impact on anti-
tumor immune responses in preclinical models, which also
holds in early-phase trials, systemic administration of recombi-
nant IL-12 has been reported to result in hepatotoxicity and
high systemic levels of IFNg.22,23 In contrast, administration of
IL-18 revealed no such toxicities in studies with melanoma and
renal cell cancer patients, however, did not reveal clinical
responses either.24-26 We argue that delivery of these two cyto-
kines directly at the site of the tumor, either alone or together,
will minimize toxic effects and at the same time maximize
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immune-stimulatory effects. In earlier studies, we have shown
that the use of CAR-engineered T cells with inducible IL-12
(iIL-12) enhanced tumor killing without toxicity by increasing
the numbers and activation of tumor inﬁltrating macro-
phages.18 In the current study, we have extended these ﬁndings
and exploited TCR-engineered T cells to provide antigen-spe-
ciﬁc and intra-tumoral release of IL-12 and IL-18, and investi-
gated the impact of these enhanced T cells on tumor growth,
toxicity, T cell phenotype and function.
Materials and methods
Cell culture and reagents
The human embryonic kidney 293 T and Phoenix-Amp cell
lines, both used to package retroviruses carrying RNA encoding
TCRab and/or iIL-12 or iIL-18, were grown in DMEM with
10% (v/v) Fetal Bovine Serum (FBS; Greiner Bio-one Alphen a/d
Rijn, The Netherlands), 200 nM L-glutamine, 1% (v/v) MEM
non-essential amino acids and antibiotics (DMEM complete).
Clones derived from mouse melanoma cell lines B16BL6
(B16WT) and B16:A2-YLEP (gene-engineered to express a
fusion protein between the human glycoprotein (gp)100280-288
epitope (YLEPGPVTA) and the HHD molecule27) were cultured
using the same medium, which in case of B16:A2-YLEP cells
contained neomycin (1 mg/ml) (G418, Calbiochem, La Jolla,
CA). In order to enhance HLA-A2 transgene expression, B16
cells were pre-treated with 100 IU/ml murine IFNg (Sanquin,
Amsterdam, The Netherlands) for 24 hours prior to in vitro
assays. Mouse splenocytes were cultured in mouse T cell
medium consisting of RPMI 1640 medium supplemented with
25 mM HEPES, 200 nM L-glutamine, 10% FBS, 1% MEM non-
essential amino acids, 1 mM sodium pyruvate, 50 mM b-mer-
captoethanol, antibiotics and 50 IU/ml human recombinant IL-2
(Proleukin; Chiron, Amsterdam, The Netherlands). For ﬂow
cytometry the following antibodies and pMHC multimer were
used: anti-TCR-Vb14-FITC (Beckman Coulter, Fullerton, CA);
CD3-PE, CD3-BV510, Ly6G-PE-Cy7, CD8-APC-Cy7, F4/80-
APC-Cy7, CD4-BV650, 4-1BB-BV421, LAG3-BV421 (all BD
Biosciences, San Jose, CA); TIM3-APC, BTLA-APC, PD-1-PE-
Cy7, OX40-APC (all Biolegend, San Diego, CA); CD45-FITC,
OX40-PE, CTLA4-PE, 4-1BB-PE, CD40 L-PE, CD4-Qdot605,
LAG3-APC, ICOS-APC, ICOS-PE-Cy7, CD14-PerCP, CD335-
eF660 (all eBiosciences, San Diego, CA); and gp100/A2Kb
pMHC tetramer-PE (a kind gift by Prof. Andrew Sewell, Cardiff
University, UK). For immunoﬂuorescent stainings, the following
primary and secondary antibodies were used: rat anti-mouse
CD3 (clone 17A2), rat anti-mouse CD335 (clone 29A1.4), rat
anti-mouse Ly6G (clone RB6-8C5) (all three from eBiosciences)
and rat anti-mouse CD68 (clone FA-11; BioLegend); and donkey
anti-rat IgG Alexa Fluor 488 (Life Technologies, Carlsbad,
California, USA).
TCR and inducible IL-12 and IL-18 constructs
TCRa and b genes speciﬁc for the human gp100280-288 epitope
presented by HLA-A2 (gp100/A2) were derived from CTL-296
clone,28 murinized and codon-optimized as described earlier.29
Subsequently, TCR genes were cloned into the pMP71 vector
(kindly provided by prof. Wolfgang Uckert, Max-Delbr€uck
Center, Berlin, Germany) with TCRa and b genes separated by
an optimized T2 A ribosome skipping sequence. Sequences of
murine IL-12 (a linked dimer consisting of p35 (NM_000882)
and p40 (NM_002187)) and the processed form of IL-18
(NM_001562) were ordered from Geneart (not codon-opti-
mized) and cloned into a pSIN vector, which contains 6 repeats
of the NFAT response element and a minimal mIL-2 promotor,
as described in.18 The plasmids with iIL-12 and iIL-18 contain a
neomycin resistance gene to allow for selection of transduced T
cells.
T cell transduction
Total mouse splenocytes were isolated, activated with Con-
canavalin A (0.5 mg/ml) and rhIL-2 in mouse T cell
medium, and transduced with retroviral supernatant from a
co-culture of single construct (either TCR, iIL-12 or iIL-18)
transfected 293 T and Phoenix-Amp cell lines as described
by Pouw and colleagues.29 To generate T cells that express
TCR and either iIL-12 or iIL-18, T cells were simulta-
neously incubated with two retroviral supernatants in a 1:1
ratio (yielding TCRCiIL-12 or TCRCiIL-18 T cells). To
obtain T cell populations that provide an inducible source
for both cytokines, used in some experiments, TCRCiIL-12
and TCRCiIL-18 T cells were mixed in a 1:1 ratio (yielding
TCRCiIL-12CiIL-18 T cells). Control (mock) T cells were
transduced with empty retroviral vector. TCR and mock T
cells were cultured as described above, whereas T cells har-
boring (in addition to the TCR) iIL-12 or iIL-18 underwent
selection with 1 mg/ml of G418 starting at 24 h after trans-
duction and lasting for 72 h (for a detailed ﬂowchart of the
T cell activation, transduction and selection procedure,
please see Fig. 1A and supplementary ﬁgure 1 A, B).
Adoptive T cell therapy
Experiments with mice were approved by the Experimental
Animal Committee of the Erasmus MC Cancer Institute
and carried out in accordance with institutional and
national guidelines. For adoptive T cell therapy studies we
used HLA-A2 transgenic (tg) mice that express a chimeric
HLA-A0201 transgene (HHD, referred to as HLA-A2).30
Adoptive transfer of T cells was done as described before.27
In short, at day -15, HLA-A2 tg mice were injected subcu-
taneously with 0.5 £ 106 of a B16:A2-YLEP clone and at
days -4 and -3 mice received a total of two Busulfan injec-
tions intraperitoneally (16.5 mg/kg ea.), followed a day later
by a single Cyclophosphamide injection intraperitoneally
(200 mg/kg). In some experiments, the mice were not
transplanted with tumor cells, but followed the same condi-
tioning and T cell treatment protocol. Mice were treated
with T cells at day 0 and grouped according to one of the
following treatments: mock T cells (number of T cells equal
to TCR T cell group); TCR T cells (total number corrected
for 7.5 £ 106 transduced T cells); TCRCiIL-12 T cells;
TCRCiIL-18 T cells; and TCRCiIL12C18 T cells). Tumor
growth was measured by caliper 3 times a week and tumor
volumes were estimated with the formula 0.4 x (AxB2)
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where A represents the largest diameter and B the diameter
perpendicular to A. Tumor regression or response to treat-
ment was deﬁned as a >30% reduction in size compared to
day 0, while relapse was deﬁned as a size-increase of the
tumor over the course of at least 3 days preceded by
response to treatment. Survival was monitored daily for up
to 45 days after administration of T cells. Body weight and
edema like symptoms were recorded starting at the day of
tumor inoculation and every third day thereafter. Peripheral
blood was collected at day 6 after T cell transfer and at
weekly intervals thereafter and used to determine numbers
of administered T cells, whereas plasma was collected at
days 16 and day 21 and used to measure cytokine levels.
Tumor tissues of regressing tumors were collected at day 5
after T cell transfer and snap-frozen in liquid nitrogen and
stored at -80C for downstream assessment of cytokines in
tumor lysates and performance of in situ immune ﬂuores-
cence. Another part of tumor tissue was directly processed
into TIL suspensions. To this end, tissue was cut into
smaller fragments, incubated with collagenase (1 mg/ml;
Sigma, St. Louis, MI) for 45 minutes at 37C, checked
microscopically and washed prior to ﬂow cytometry.
Figure 1. Protocol to generate T cells equipped with a TCR and an inducible cytokine construct. (A) Timeline for transduction procedure that yields TCR- and induced (i)
cytokine-positive T cells Optimization of individual aspects of the procedure are described in materials and methods and supplementary ﬁgure 1. (B) At the end of T cell
selection (day 7 after T cell activation) T cells that were transduced with TCR and iIL-12 or TCRCiIL-18 were labeled with CD8-APC antibody and gp100/HLA-A2 tetramer-
PE. Mock and TCR-only transduced T cells were stained as controls. T cells were gated for live cells and dotplots are representative of three different experiments. Percen-
tages in upper right quadrants represent fractions of CD8C T cells binding to tetramer.
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Flow cytometry
T cells or TILs (5 £ 105) were washed with PBS and incubated
with antibodies at 4C or with pMHC multimers at 37C for
30 min. Following staining, T cells were washed again and ﬁxed
with 1% paraformaldehyde. Absolute T cell counts in mouse
blood samples were determined using Flow-Count Fluoro-
spheres. Events were acquired on a FACS Canto ﬂow cytometer
and analysed using FCS Express 4 software (BD Biosciences).
Measurement of cytokines
T cells (6 £ 104/well of 96-wellsplate) were co-cultured with
either antigen-positive or negative B16 cells (2 £ 104/well) in a
total volume of 200 ml of T cell assay medium (RPMI 1640, L-
glutamine, 10% FBS, and antibiotics) for 24 h at 37C and 5%
CO2. Stimulation with medium was used as a control. Subse-
quently, supernatants were harvested and used to determine
cytokine levels by standard ELISAs (IL-2, IL-10, IL-12, IFNg,
TNFa: eBioscience, San Diego, CA; IL-18: MBL, Nagoya,
Japan). Plasma levels of selected cytokines were measured using
the ProcartaPlex Mouse Th1/Th2/Th9/Th17/Th22/Treg Cyto-
kine Panel (eBioscience) according to manufacturer’s instruc-
tions. Tumor lysates were generated following sonication (3
cycles of 10 s using SoniPrep 150, MSE, London, UK) of frozen
tissue suspended in PBS with protease inhibitors (Protease
inhibitor cocktail tablets, Roche), and subsequently analyzed
for concentrations of IL-12 and IL-18 via ELISA.
In situ immune ﬂuorescence
Tissue sections were cut at 5 mm and ﬁxed with acetone for
10 min, dried, washed, and blocked with PBS/10% donkey
serum/0.3% Triton for 30 min prior to immune staining. Next,
sections were incubated with the primary antibody overnight at
4C, washed and incubated with the donkey anti-rat IgG Alexa
Fluor 488 for 2 h at room temperature in the dark. Sections
were covered with Vectashield, and kept subsequently at room
temperature for 2 h and at 4C overnight. Sections were exam-
ined microscopically (Leica, DM IL, 200x magniﬁcation) and
photographed (Leica DFC 3000G camera and LAS4 software).
Recorded photographs were analyzed using Fiji software.31 The
number of pictures from each tumor ranged between 12 and
16, and using an in-house developed algorithm, the mean num-
ber of positively stained cells was determined, and normalized
for percentages of nucleated cells (DAPI staining).
Statistical analyses
The different treatment groups were compared with the Stu-
dent’s t-tests, or the Mantel-Cox test in case of survival data,
using GraphPad Prism5 (GraphPad Software, La Jolla, CA). P
values < 0.05 were considered statistically signiﬁcant.
Results
TCRCiIL-12 T cells, and to a lesser extent TCRCiIL-18 T
cells, produce enhanced levels of IFNg
We developed a protocol that yielded high numbers of T cells
transduced with both the gp100/HLA-A2-speciﬁc TCR and
iIL-12 or IL-18. Such inducible T cells showed maximal respon-
siveness towards antigen-positive tumor cells (see Fig. 1A and
supplementary ﬁgure 1 ACB for details). Surface expression of
TCR genes and binding to cognate pMHC ranged between 65–
75%, irrespective of the presence of iIL-12 or iIL-18 (Fig. 1B).
TCRCiIL-12 T cells produced >5.5 ng/106 cells of IL-12, and
TCRCiIL18 T cells produced >75 pg/106 cells of IL-18 upon
co-culture with antigen-positive cells (see Fig. 2A). Co-cultur-
ing TCRCiIL-12 T cells and TCRCiIL-18 T cells at a 1:1 ratio
(TCRCiIL-12CiIL-18) demonstrated an expected drop in the
antigen-speciﬁc production of IL-12 and IL-18. Notably, T cells
that harbor iIL-12 produced minor amounts of IL-12 indepen-
dent of TCR engagement, which was not the case for T cells
harbouring iIL-18 (see Fig. 2A). When testing antigen-speciﬁc
production of IFNg by these T cell populations, we observed a
signiﬁcant increase in case T cells harbored iIL-12, iIL-18 or
both (see Fig. 2B) when compared to TCR T cells. TCRCiIL-12
and TCRCiIL-12CiIL-18 T cells produced more than twice as
much IFNg than TCRCiIL-18 T cells. Furthermore, testing for
antigen-speciﬁc production of IL-10 revealed that both
TCRCiIL-12 and TCRCiIL-12CiIL-18 T cells produced signiﬁ-
cantly increased levels of this cytokine. While the various T cell
populations also produced IL-2 as well as TNFa upon co-cul-
ture with antigen-positive B16 cells, their levels of were not
affected by either iIL-12, IL-18 or both (see Fig. 2B).
Treatment of melanoma-bearing mice with TCRCiIL-18 T
cells results in more cures, yet treatment with TCRCiIL-12 T
cells adversely affects survival
We treated HLA-A2 transgenic mice with palpable B16:A2-
YLEP tumor (»400 mm3) either with 7.5£ 106 TCR, TCRCiIL-
12, TCRCiIL-18, TCRCiIL-12CiIL-18 or mock T cells (see
Materials and Methods for details). In the TCR T cell group,
66% of mice showed tumor regression, whereas in the
TCRCiIL-12, TCRCiIL-18 and TCRCiIL-12CiIL-18 T cell
groups these percentages were 66, 100 and 78, respectively (see
Fig. 3A; for individual tumor growth curves, see supplementary
Fig. 2). Moreover, treatment with TCR T cells resulted in com-
plete responses (i.e., no detectable tumor) until the end of the
experiment (day 45 after T cell transfer) in 11% of mice, a result
that was not improved by treatment with TCRCiIL-12 T cells
(see Fig. 3B). In contrast, treatment with TCRCiIL-18 or
TCRCiIL-12CiIL-18 T cells resulted in complete responses in
33% of mice. In addition, in the group treated with TCRCiIL-12
T cells, mice suffered from tumor recurrence at earlier time
points than mice in the group treated with TCRCiIL-18 T cells
(see supplementary Fig. 2). Fig. 3B provides an overview of the
fractions of complete, partial and no responses among the differ-
ent treatment groups. When assessing survival, 29% and 14% of
mice treated with TCR or TCRCiIL-12 T cells were alive at the
end of experiment, respectively, whereas 57% and 43% of mice
treated with TCRCiIL-18 or TCRCiIL-12CiIL-18 T cells were
alive at the end of experiment (see Fig. 3C). Treatment-related
mortality, deﬁned as death of mice after T cell treatment not
coinciding with tumor outgrowth, occurred in TCRCiIL-12 and
TCRCiIL-12CiIL-18 T cell-treated mice, with percentages of
mice that died within 14 days after T cell transfer being 33 and
22, respectively. Treatment-related mortality was absent in the
e1378842-4 A. KUNERT ET AL.
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TCR and TCRCiIL-18 T cell-treated mice (see Fig. 3B). Along
these lines, we observed enhanced loss of weight in 56–78% (see
supplementary Fig. 3) as well as edema-like toxicities in 29% of
the treatment groups with iIL-12. Table I provides details on
observed therapy-related effects.
Administration of TCRCiIL-12 T cells results
in compromised T cell persistence and enhanced
plasma levels of inﬂammatory cytokines
As peripheral T cell persistence has been directly linked to clin-
ical anti-tumor efﬁcacy,32 blood samples were taken at various
time points after T cell transfer and analyzed by ﬂow cytometry
for the presence of TCR-engineered T cells. We observed
increased numbers of pMHC-binding T cells in blood of
TCRCiIL-18 and the TCRCiIL-IL-12CiIL-18 T cell-treated
mice at day 6 after T cell transfer when compared to TCR T
cell-treated mice (see Fig. 4A). Numbers of pMHC-binding T
cells were decreased in the blood at day 6 after treatment with
TCRCiIL-12 T cells. It is noteworthy, that the ratio of CD8 to
CD4 positive T cells was signiﬁcantly enhanced in the treat-
ment groups that received treatment with iIL-18 when com-
pared to the TCRCiIL-12 group (see Fig. 4B). These ﬁndings
are in line with our in vitro observation that cultures of
Figure 2. Inducible T cells produce IL-12 and IL-18 upon recognition of cognate antigen, which results in enhanced production of IFNg . T cells were transduced with one
or a combination of the following constructs: empty retroviral vector (mock); gp100 TCR (TCR); gp100 TCR and iIL-12 (TCRCiIL-12); gp100 TCR and iIL-18 (TCRCiIL-18). In
an additional set of experiments, TCRCiIL-12 and TCRCiIL-18 T cells were mixed at a 1:1 ratio (TCRCiIL-12CiIL-18). These T cell populations were co-cultured with B16
melanoma cells that were either positive or negative for the gp100 target antigen at an effector:target (E:T) ratio of 3:1 for 24 h. As a control, T cells were cultured in
medium only. (A) Levels of IL-12 and IL-18 in culture supernatants were measured via ELISA, and displayed as mean cytokine production per 106 T cells §SEM (n D 5). (B)
Levels of IFNg , IL-10, IL-2 and TNFa in culture supernatants were measured via ELISA, and displayed as mean cytokine production per 106 T cells §SEM (n D 5). Statisti-
cally signiﬁcant differences between T cell populations that were co-cultured with antigen-positive B16 cells were calculated with Student’s t-test: p<0.05; p<0.01;
p<0.005.
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TCRCiIL-12 T cells yielded lower cell numbers when com-
pared to cultures of TCRCiIL-18 or TCR T cells (see supple-
mentary ﬁgure 1 A, lower panel). In addition to whole blood,
we also collected plasma samples on day 16 after T cell transfer,
which were analyzed via multiplex assay for the presence of
cytokines (see Fig. 5). While plasma levels of IL-12 were low in
all treatment groups (<7 pg/ml), plasma levels of IL-18 were
considerably high in all groups (>700 pg/ml) and highest in
mice treated with TCRCiIL-12CiIL-18 T cells (>1300
pg/ml). Of interest, in particular in relation to the above-
mentioned toxicities, is the observation that plasma levels of
IFNg and TNFa were signiﬁcantly higher in the TCRCiIL-12
and TCRCiIL-12CiIL-18 T cell groups (and negligible in the
TCR and TCRCiIL-18 T cell groups). IL-2 plasma levels
showed no signiﬁcant difference among the tested groups.
Figure 3. Treatment with TCRCiIL-18 T cells reduces tumor growth and prolongs survival. HLA-A2 transgenic mice bearing established tumors derived from
inoculated B16:A2-YLEP cells were conditioned with Busulfan and Cyclophosphamide and treated with 7.5 £ 106 T cells that were mock transduced or trans-
duced with TCR, TCRCiIL-12, or TCRCiIL-18; or mice were treated with a mixture of 3.75 £ 106 T cells transduced with TCRCiIL-12 and 3.75 £ 106 T cells
transduced with TCRCiIL-18 (TCRCiIL-12CiIL-18). (A) Waterfall graph of percentage change in tumor size between days 3 and 14 after T cell transfer, with
each bar representing a single mouse. Tumor sizes were measured three times a week with a caliper. Dashed lines indicate average tumor size per treatment
group. ‘y’ indicates death of mouse, in which case latest record of tumor size has been used. (B) Stacked bars representing percentages of mice with different
responses to therapy at day 45 after T cell transfer. Complete response is deﬁned as absence of a palpable tumor at the end of the experiment (day 45); par-
tial response is deﬁned as  30% tumor regression followed by relapse; no-response is deﬁned as < 30% tumor regression; and therapy-related death is
deﬁned as death not coinciding with tumor progression (n D 9 per group). (C) Survival curves of treatment groups. Two mice of each group were sacriﬁced at
day 5 after T cell transfer to collect tumors and are omitted from this ﬁgure (n D 7 per group).
Table 1. Therapy-related side-effects of T cells gene-engineered with TCR and
iIL-12 and/or iIL-18.
Treatment
Maximum
weight lossa Edemab
Therapy
-related deathc
Overall
survivald
mock 57% 0% 0% 0%
TCR only 11% 0% 0% 29%
TCRCiIL-12 78% 29% 43% 14%
TCRCiIL-18 0% 0% 0% 57%
TCRCiIL-12CiIL-18 56% 29% 29% 43%
apercentage of mice showing a loss of weight exceeding 10% of starting weight
(day -15).
bpercentage of mice developing edema; mice were scored positive for edema
according to both, visual evaluation by a pathologist and increase in body weight
of >3.0% per day over a period of 7 or more days.
cpercentage of mice dying within the ﬁrst 10 days after T cell administration while
no tumor growth was detected.
dpercentage of mice alive at day 45.
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Plasma levels of IL-10 were increased in mice treated with
TCRCiIL-12 T cells compared with those mice treated with
TCRCiIL-18 and TCRCiIL-12CiIL-18 T cells.
Treatment with TCRCiIL-18 T cells results in enhanced
accumulation of CD8 and TCR-transgene-positive T cells
within the tumor
To better understand the in vivo behavior of TCRCiIL-12
and TCRCiIL-18 T cells, we assessed how the different
treatments affect T cell inﬁltration into solid tumors and
the phenotype of intra-tumoral T cells. To this end, we
have performed ﬂow cytometry analyses of TILs and
observed an enhanced frequency of CD8CTCRC T cells
amongst CD3C TILs upon treatment with TCRCiIL-18 T
cells when compared to TCRCiIL-12 T cells (39 vs 9%) (see
Fig. 6A, left graph). Looking into the ratio of CD8C and
CD4C T cells, it became apparent that treatment with
TCRCiIL-18 but not with iIL-12 T cells results in an
enrichment of CD8C TILs (» 7 vs 0.5, respectively; see
Fig. 6A, right graph). Next, we studied the phenotype of
TILs, in particular with respect to co-stimulatory as well as
co-inhibitory receptor expression. The analysis of percen-
tages of individual co-stimulatory or co-inhibitory receptors
by CD8C TILs, nor analysis of their co-expression by these
cells, revealed no signiﬁcant difference between treatment
groups (see Fig. 6B and C). Also, phenotypic differences
were not observed when analyzing CD4C TILs or analyzing
mean ﬂuorescence intensities (data not shown).
Mice treated with TCRCiIL-12 T cells demonstrate
extensive intra-tumoral inﬁltration of macrophages
In addition to numbers and phenotype of intra-tumoral T
cells, we also assessed the cellular composition of the
immune inﬁltrate in more detail. TILs from the different
treatment groups were assessed by ﬂow cytometry for the
presence of T cells (CD3C), macrophages (CD68C), NK cells
(CD335C) and neutrophils (Ly6GC). Strikingly, we observed
that frequencies of macrophages were increased in mice
receiving TCRCiIL-12 T cells, an observation that went
hand in hand with a decrease in frequencies of T cells (see
Fig. 7). Neither NK cell nor neutrophil numbers showed
signiﬁcant differences between treatment groups. To sub-
stantiate these ﬁndings we assessed the presence of IL-12
and IL-18 in lysates from the same tumor, and showed that
the concentrations of IL-12 were higher in tumors from the
groups treated with TCRCiIL-12 or TCRCiIL-12CiIL-18 T
cells, whereas the concentrations of IL-18 were higher in
tumors from the groups treated with TCRCiIL-18 when
compared to treatment with TCR T cells. Endogenous levels
of IL-18 ranged between 400 and 1000 pg/ml, while those
of IL-12 were below 100 pg/ml (see supplementary Figure 4
A). Furthermore, we also assessed the composition of the
immune inﬁltrate using in situ immune ﬂuorescence, and
quantiﬁed the various immune cell types per area tumor tis-
sue. The numbers of T cells (CD3C), macrophages (F4/80C),
NK cells (CD335C) and neutrophils (Ly6GC) that were
found in the tumors from the different treatment groups
conﬁrmed the ﬁndings of the ﬂow cytometric analysis (see
supplementary Figure 4B and C). It is noteworthy that NK
cells and neutrophils were readily detectable by ﬂow cytom-
etry, while staining for the same markers in tissues slices
yielded no to negligible detection of either cell type. This
discrepancy between both techniques most likely relates to
the use of different antibodies in different applications.
Discussion
In this study, we compared the therapeutic impact of IL-12
and/or IL-18 secretion at the tumor site by antigen-triggered
T cells. To this end, we equipped murine T cells both with
gp100-speciﬁc TCRa/b genes and an inducible cytokine
Figure 4. Treatment with TCRCiIL-12 T cells results in lowered numbers of CD8 and TCR transgene-positive T cells in blood. HLA-A2 transgenic mice bearing established
B16:A2-YLEP tumors were conditioned and treated with T cells as described in legend to Figure 3. (A) Peripheral blood was collected from mice at the indicated time
points after T cell transfer and absolute numbers of gp100/HLA-A2 pMHC-binding CD8 T cells were determined by ﬂow cytometry. Data are presented as mean numbers
per ml blood§SEM (n D 4–6). (B) depicts the mean ratio of CD8/CD4 positive therapeutic T cells at day 6 after T cell transfer §SEM (n D 4–6). Statistically signiﬁcant dif-
ferences between treatment groups were calculated with Student’s t-test: p < 0.05;  p< 0.01.
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construct. T cells were antigen-responsive and, besides being
producers of IL-12 or IL-18, produced enhanced levels of
IFNg. The production of IFNg was prominent in case of
TCRCiIL-12 T cells and highest in TCRCiIL-12CiIL-18 T
cells, which is in line with previous reports where T cells
were exposed to a combination of recombinant IL-12 and
IL-18.33 TCR T cells harboring iIL-18, when transferred to
mice bearing melanoma positive for the gp100 target antigen,
resulted in enhanced and more durable anti-tumor responses
when compared to T cells engineered with a TCR only or
TCR and iIL-12. Furthermore, treatment with TCRCiIL-18
T cells, but not TCRCiIL-12 T cells, prolonged survival
when compared to treatment with TCR T cells.
The low survival in the TCRCiIL-12 T cell treatment group
is most likely a result of IL-12-mediated toxicities. Mice receiv-
ing TCRCiIL-12 or TCRC iIL-12CiIL-18 T cells demonstrated
elevated plasma levels of IFNg and TNFa, clear weight loss,
edema-like symptoms and in some cases death. The detection
of IFNg and TNFa in plasma is considered a consequence of
IL-12-mediated productions of these cytokines by tumor-inﬁl-
trating immune cells.34 IFNg is most likely derived from
administered T cells following inﬁltration and activation in the
tumor tissue. This notion is strengthened by our observation
that CD335-positive NK cells, as an alternative source of IFNg,
were only present at low frequency within the tumors of treated
mice. TNFa is most likely derived from macrophages since we
Figure 5. Treatment with TCRCiIL-12 T cells results in increased plasma levels of inﬂammatory cytokines. Plasma samples were collected from mice on days 16 and 21
after T cell transfer and were screened for the presence of multiple cytokines via multiplex assay (“ProcartaPlex Mouse Th1/ Th2/ Th9/ Th17/ Th22/ Treg Cytokine Panel
(17 plex)” by eBioscience). Concentrations of IL-12, IL-18, IFNg , IL-2, TNFa and IL-10 on day 16 are presented as mean§SEM (n D 3). Statistically signiﬁcant differences
between treatment groups were calculated with Student’s t-test: p < 0.05; p < 0.01.
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detected an enhanced frequency of CD68 as well as F4/80-posi-
tive macrophages in tumors isolated from mice treated with
TCRCiIL-12 T cells, and in vitro assays revealed no enhanced
TNFa production by these T cells. Collectively, our ﬁndings
extend previous clinical studies, where systemic administration
of recombinant protein or cDNA encoding IL-12 was reported
to result in enhanced production of IFNg and TNFa, changes
in blood vessel wall permeability, edema and even sepsis-like
symptoms.34,35 In fact, a recent study demonstrated that treat-
ment of melanoma patients with iIL-12-transduced TILs was
accompanied by liver dysfunction, high fever, and hemody-
namic instability.36 To further assess the observed toxicities, we
also treated mice without tumor-implant with TCRCiIL-12 T
cells and still observed enhanced weight loss when compared to
mice treated with TCR T cells (see supplementary ﬁgure 3).
These ﬁndings extend our in vitro observations showing target-
independent release of IL-12 by these T cells (Fig. 2A) as well
as those by Zhang and colleagues, who also reported non-spe-
ciﬁc release of IL-12 and reduced ﬁtness when culturing iIL-12-
expressing TILs.36 It is noteworthy that none of the mice with-
out a tumor implant developed edema or showed therapy-
related mortality, arguing that although toxicities are
related to antigen-independent release of IL-12, they may
exacerbate in the presence of antigen-positive tumor cells.
Non-speciﬁc release of IL-12, in particular in the setting of
TCR-engineered T cells, may be explained by the size of
the inserted construct. IL-12 is a relatively large cytokine
with 550 aa, while IL-18 encompasses 192 aa and, like
Figure 6. Upon treatment with TCRCiIL-18 T cells, numbers of CD8-positive TILs are enhanced without a change in expression of co-signaling receptors. Mice with
regressing tumors (treated with TCR T cells with or without inducible cytokines) were sacriﬁced (n D 4 per group). TILs were isolated as described in Materials and Meth-
ods and analyzed via ﬂow cytometry for the expression of CD3, CD4, CD8, TCR, 4–1BB, CD40 L, ICOS, OX40, PD-1, TIM3, LAG3 and CTLA-4. (A) depicts the percentage of
CD8CTCRC T cells amongst CD3C TILs (left panel) and the CD8/CD4 ratio of TCRC T cells within CD3C TILs. Bars in (B) show the mean expression of individual co-stimula-
tory (left panel) and co-inhibitory (right panel) receptors of CD3CCD8C TILs. (C) provides an overview of the degree of co-expression of co-stimulatory receptors (upper
charts) as well as co-inhibitory receptors (lower charts). Statistically signiﬁcant differences between treatment groups were calculated with Student’s t-test: p < 0.05.
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other smaller constructs we tested (data not shown), shows
no antigen non-speciﬁc release. Finally, we cannot exclude
the contribution of host, co-treatment and tumor to the
observed toxicities. In one of our earlier studies, where we
tested iIL-12 in mouse models utilizing CAR-transduced T
cells,18 we did not observe the toxicities as reported in this
study, which may suggest that mouse strain (C57 BL/6 vs
NIH-III), pre-conditioning protocol (Busulfan/Cyclophos-
phamide vs no pre-treatment), and type of tumor (mela-
noma cells vs colon carcinoma cells) affect the extent of
IL-12-mediated toxicities.
Treatment with TCRCiIL-18 T cells, not revealing any
toxicity, resulted in clearly enhanced anti-tumor responses.
To better understand the immune-enhancing effect of this
treatment, we have assessed numbers and phenotype of
intra-tumoral T cells as well as the presence of other
immune cell types within tumors. Notably, we observed an
enhanced density of TCR-transduced TILs, in particular of
the CD8 subset, when mice were treated with TCRCiIL-18
but not TCRCiIL-12 T cells. Enhanced numbers of CD8C T
cells within tumors are generally considered a beneﬁcial fac-
tor with respect to tumor evolution and therapy
response.7,37,38 The differential treatment effect with respect
to numbers of TILs can be explained by two lines of argu-
ments. First, our in vivo analysis of tumors showed that
treatment with TCRCiIL-12 when compared to TCRCiIL-18
T cells results in an enhanced presence of macrophages (see
Fig. 7 and supplementary Fig. 4). These results, together
with enhanced TNFa levels in sera, argue that macrophages
and their product TNFa may limit the inﬁltration of CD8C
T cells as was observed previously using various mouse mod-
els.39,40 Second, in vitro analysis of T cells demonstrated that
iIL-18 when compared to iIL-12 provides T cells with high
expression of co-stimulatory receptors and a low expression
of co-inhibitory receptors (see supplementary ﬁgure 5).
These traits may be representative of a preferred T cell phe-
notype at the time of adoptive transfer for an effective tumor
response. Interestingly, when studying the phenotype of TILs,
we observed no signiﬁcant differences in the expression of co-
stimulatory or inhibitory receptors by CD8C TILs. When zoom-
ing in on TCR transgene-expressing TILs, however, we did
observe that treatment with TCRCiIL-18 T cells resulted in
enhanced expression of the co-stimulatory receptor ICOS and
the co-inhibitory receptors PD-1 and CTLA-4, whereas treat-
ment with TCRCiIL-12 T cells resulted in enhanced expression
of the co-stimulatory receptors 4–1BB and CD40 L and the co-
inhibitory receptors LAG3 and CTLA-4 (see supplementary
ﬁgure 6). These latter data are difﬁcult to interpret given the fact
that numbers of TCRC TILs are extremely low in case of treat-
ment with TCRCiIL-12 T cells. With respect to treatment with
TCRCiIL-18 T cells, ICOS may contribute to enhanced tumor
inﬁltration and prolonged T cell persistence as was demonstrated
in adoptive T cell therapy studies (41; Kunert, manuscript in
preparation). PD-1, on the other hand, may mark successful
antigen-speciﬁc TCR triggering and T cell activation.42 Notably,
the fact that TCRCiIL-12 T cell treatment, when compared to
TCRCiIL-18 T cells, results in the highest CTLA-4 and LAG3
expressions may provide an additional explanation for their low-
ered ability to mediate tumor clearance.
The above ﬁndings argue that IL-12 has potent immune-
stimulatory effects, which may rapidly initiate the expression
of immune checkpoints. In an effort to downscale negative
feedback on T cell activation, we titrated down TCRCiIL-12
T cells and observed that lowering the numbers of these cells
did not change the effects this cytokine has on the production
of IFNg nor the expression of PD-1 (supplementary Figure 7;
same results were observed for production of IL-10 and
expression of FOXP3, data not shown), arguing that it is difﬁ-
cult to maintain beneﬁcial effects of IL-12 towards anti-tumor
T cell activity while preventing the induction of a negative
feedback. These data, together with the toxic effects we noted
when using TCRCiIL-12 T cells, do not favor further thera-
peutic studies with T cells carrying iIL-12.
In conclusion, our ﬁndings demonstrate that the thera-
peutic use of TCR-engineered T cells equipped with induc-
ible IL-12 leads to limited anti-tumor effects and severe
toxicities in vivo, in part due to antigen non-speciﬁc release,
whereas equipment of TCR T cells with inducible IL-18
results in enhanced anti-tumor responses without toxicities,
most clearly related to increased accumulation of CD8
and TCR-transgene-positive T cells within tumors. Taken
together, these ﬁndings advocate further studies towards the
Figure 7. Mice treated with TCRCiIL-12 T cells show an enhanced number of tumor-inﬁltrating macrophages. Following T cell treatment, regressing tumors were col-
lected at day 5 after T cell transfer. Tumors were dissociated into a single-cell suspension, stained with antibodies directed against CD3 (T cells), CD68 (macrophages),
CD335 (NK cells) or Ly6G (neutrophils), and analyzed by ﬂow cytometry. Figure depicts the mean number for each cell type§SEM (nD 4). Statistically signiﬁcant differen-
ces between treatment groups were calculated with Student’s t-test: p < 0.05; p < 0.01.
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use of iIL-18 T cells to address therapy resistance in the set-
ting of adoptive T cell therapy.
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